October 16, 2023
Gibson Dunn advised KKR Health Care Growth Fund II on its investment in German biopharmaceutical research and development company Coriolis Pharma.
As part of the deal, Coriolis Pharma will enter into a strategic growth partnership with Frontier Biosolutions, a global pharma services platform newly formed by KKR and Flerie Invest AB.
KKR’s investment will enable Coriolis to initiate the next phase of growth in its core business, expand its service portfolio along the value chain, strengthen its presence globally, and continue to integrate AI-based technologies.
The Gibson Dunn team representing KKR Health Care Growth was led by co-head of private equity in Europe Wim De Vlieger alongside private equity partners Wilhelm Reinhardt and Jan Schubert, with support from counsel Jakob Egle and associates Sonja Ruttmann, Dennis Seifarth, Lisa Hollfelder and Gisele Zouein.
The team was also supported by antitrust and competition partner Attila Borsos, as well as associates Ben Nunez and Robert Albertson Kill, corporate associate Marcus Geiss and counsel Birgit Friedl, intellectual property partner Kai Gesing and associates Christoph Jacob and Yannick Oberacker, and finance counsel Alexander Klein along with associate Bastiaan Wolters.